CompletedNot Applicable

Salt Supplementation in Gitelman Syndrome

Italy, Netherlands21 participantsStarted 2021-04-19

Plain-language summary

The purpose of this study is to determine the effect of salt (NaCl) supplementation on serum potassium and clinical signs and symptoms in patients with Gitelman syndrome.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Genetically-proven, symptomatic Gitelman syndrome * Written informed consent Exclusion Criteria: * inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics * pregnancy

What they're measuring

Change in serum Potassium

Timeframe: Baseline, week 4, week 8, week 12, week 16, week 20, week 24

Change in symptoms measured by personalized symptom score sheet

Timeframe: Weekly (week 0 till week 24)

Trial details

NCT IDNCT04995627

SponsorRadboud University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-01

View on ClinicalTrials.gov More Gitelman Syndrome trials